Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | POLB | P06746 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 7/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.57 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | CRHBP | P24387 | 3/20 | 0.56 |
| ▸ | CRHR2 | Q13324 | 3/20 | 0.56 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 4/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30384717 | 1.00 | SMN1; SMN2 (0.64) | SMN1; SMN2LMNAALDH1A1POLBL3MBTL1 | |
| SCHEMBL962472 | 0.88 | HTT (0.62) | SMN1; SMN2LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL13212301 | 0.84 | CYP19A1 (0.54) | SMN1; SMN2LMNAALDH1A1POLBL3MBTL1 | |
| SCHEMBL6074073 | 0.82 | SMN1; SMN2 (0.69) | SMN1; SMN2LMNAALDH1A1POLBL3MBTL1 | |
| SCHEMBL27976139 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2LMNAALDH1A1POLBL3MBTL1 | |
| SCHEMBL30311318 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2LMNAALDH1A1POLBL3MBTL1 | |
| SCHEMBL20302624 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2LMNAALDH1A1POLBL3MBTL1 | |
| SCHEMBL18549285 | 0.81 | SMN1; SMN2 (0.68) | SMN1; SMN2LMNAALDH1A1POLBL3MBTL1 | |
| SCHEMBL38652551 | 0.81 | AKR1C3 (0.46) | SMN1; SMN2LMNAALDH1A1POLBL3MBTL1 | |
| SCHEMBL3248880 | 0.80 | LMNA (0.69) | SMN1; SMN2LMNAALDH1A1POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1866307-A1 | SYNTHESIS OF PYRROLOQUINOLINE QUINONE (PQQ) | CLF Medical Technology Acceleration Program, Inc. (US) | 2007-12-19 | — | — | EP | claimed |
| US-20070072894-A1 | Synthesis of pyrroloquinoline quinone (PQQ) | CLF MEDICAL TECHNOLOGY ACCELERATION PROGRAM, INC. | 2007-03-29 | — | — | US | claimed |
| WO-2006102642-A1 | SYNTHESIS OF PYRROLOQUINOLINE QUINONE (PQQ) | CLF MEDICAL TECHNOLOGY ACCELERATION PROGRAM, INC. (US) | 2006-09-28 | — | — | WO | claimed |
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | claimed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | claimed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | claimed |
| EP-4725554-A2 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | Yuhan Corporation (KR) | 2026-04-15 | — | — | EP | disclosed |
| US-RE50528-E1 | Compounds and compositions for modulating EGFR mutant kinase activities | YUHAN CORPORATION (KR) | 2025-08-12 | — | — | US | disclosed |
| EP-3929190-B1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | YUHAN CORP (KR) | 2024-12-25 | — | — | EP | disclosed |
| EP-4421069-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | Yuhan Corporation (KR) | 2024-08-28 | — | — | EP | disclosed |
| CN-111686110-B | Compounds and compositions for modulating EGFR mutant kinase activity | 株式会社柳韩洋行 | 2023-06-16 | — | — | CN | disclosed |
| EP-3929190-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | Yuhan Corporation (KR) | 2021-12-29 | — | — | EP | disclosed |
| EP-3604294-B1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | YUHAN CORP (KR) | 2021-05-05 | — | — | EP | disclosed |
| WO-2001012593-A1 | ARYLSULFONANILIDE DERIVATIVES | TULARIK INC. (US) | 2001-02-22 | — | — | WO | disclosed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | disclosed |
| US-6153585-A | FOR TREATING CANCER, PSORIASIS, VASCULAR RESTENOSIS, INFECTIONS, ATHEROSCLEROSIS AND HYPERCHOLESTEROLEMIA | TULARIK INC. (US) | 2000-11-28 | — | — | US | disclosed |
| WO-2000017159-A1 | ARYLSULFONANILIDE UREAS | TULARIK INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| US-5801170-A | Heterocyclic biphenylylamides useful as 5HT1D antagonists | SMITHKLINE BEECHAM PLC (GB) | 1998-09-01 | — | — | US | disclosed |
| EP-0733048-A1 | HETEROCYCLIC BIPHENYLYLAMIDES USEFUL AS 5HT1D ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-09-25 | — | — | EP | disclosed |
| WO-1995015954-A1 | HETEROCYCLIC BIPHENYLYLAMIDES USEFUL AS 5HT1D ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072894-A1 | Synthesis of pyrroloquinoline quinone (PQQ) | QPCT, SYNCRIP, SFPQ | SMN1; SMN2 2221/4885LMNA 3535/4885ALDH1A1 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.